<DOC>
	<DOCNO>NCT01900860</DOCNO>
	<brief_summary>We propose conduct randomize double blind trial three dos vitamin D , 400 , 4000 , 10,000 International Units ( IU ) per day , assess effect bone density architecture assess high resolution peripheral quantitative tomography ( HR-pQCT ) measurement radius distal tibia , standard Dual X-ray absorptiometry ( DXA ) . Other measure bone calcium metabolism assess . The trial last long three year . Approximately 300 healthy men woman , age 50-70 year age , recruit , randomly assign one three dose vitamin D. Other outcome variable assess include quality life , depression , muscle strength balance .</brief_summary>
	<brief_title>Dose-dependent Effects Vitamin D Bone Health</brief_title>
	<detailed_description>Hypotheses test : 1 . It hypothesize vitamin D , dose-dependent manner , suppress parathyroid hormone action , result less bone turnover , decreased cortical porosity , lead improve bone strength assess finite element analysis . 2 . It hypothesize vitamin D , dose-dependent manner , increase bone density central skeleton ( spine , hip ) , measure current standard method dual X-ray absorptiometry ( DXA ) . 3 . It hypothesize vitamin D , dose-dependent manner , impact quality life , include index depression , measure SF-36 questionnaire appropriate index depression . Outcomes : Primary outcome : - bone strength measure HR-pQCT , include assessment relative contribution trabecular cortical bone . Secondary outcome : - bone mineral density measure DXA - parameter calcium metabolism , include biochemical marker bone turnover DNA examine possible variation gene control vitamin D metabolism . - quality life score - depression scale score - balance , grip strength . - fast glucose Hemoglobin A1C also measure . - Safety assess schedule follow-up visit obtain history adverse event , well measurement serum urine parameter mineral metabolism describe . INTERVENTION DRUG : Vitamin D3 one three dos Rationale : For adult age 70 year , recent Institute Medicine ( IOM ) report recommend total intake 600 IU vitamin D/day provide vitamin D need bone health , since typical Canadian diet contain 200 300 unit vitamin D , subject low dose arm study receive 400 IU/day . The two group receive 10,000 IU 4,000 IU , respectively . The 10,000 IU dose tolerable upper intake level ( TUL ) recommend Hathcock et al ( Am J Clin Nutr 2007 ) 4,000 IU IOM 's recommended TUL . Calcium intake : All subject adequate calcium intake define Institute Medicine ( total 1200 mg/day ) . A brief dietary history take subject instructed take appropriate dose supplemental calcium daily intake less 1200 mg/day ( IOM 's Recommended Daily Allowance study population ) . Interim analysis ( maintenance blind subject investigator treatment arm ) : - plan year 1 2 , well final analysis year 3 .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Healthy woman men 55 70 year age ; woman least 5 year postmenopause . Presence chronic illness exclude participation condition stable manage physician . Baseline lumbar spine total hip bone mineral density ( BMD ) Tscore 2.5 assessed use dual xray absorptiometry ( DXA ) . A serum 25 [ OH ] vitamin D ( 25OHD ) &lt; 30 nmol/L ( &lt; 12 ng/mL ) &gt; 100 nmol/L ( 40 ng/mL ) . Hypercalcemia ( serum calcium &gt; 2.55 mmol/L ) , hypocalcemia ( serum calcium &lt; 2.10 mmol/L ) eGFR &lt; 30 mL/min . Surgical cure Primary Hyperparathyroidism within last year . Active kidney stone disease ( recurrent stone , recent kidney stone [ within last 2 year ] ) Known hypersensitivity allergy Vitamin D Serum creatinine , AST , ALT , PTH , calcium , alkaline phosphatase great 1.5 time upper limit normal screen visit BMD exclusion : 1 . High 10year risk osteoporotic fracture , define Canadian Association Radiologists/Osteoporosis Canada calculator , World Health Organization 's FRAX calculator . 2 . DXA Tscore equal 2.5 SD . Have take bone active osteoporosis prescription drug past 2 year ( bisphosphonates ) 1 year ( osteoporosis prescription therapy ) . Any medical condition would prevent participation clinical trial full three year . Medications prednisone &gt; 2.5 mg daily ( equivalent ) ; bone active medication tamoxifen aromatase inhibitor breast cancer , androgen deprivation therapy prostate cancer . Disorders know affect vitamin D metabolism sarcoidosis renal failure malabsorption disorder ( e.g . pancreatic insufficiency celiac disease ) . Regular ( monthly frequent ) use tan salon .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Vitamin D</keyword>
	<keyword>Bone quality</keyword>
	<keyword>Bone density</keyword>
	<keyword>calcium metabolism</keyword>
	<keyword>High resolution peripheral quantitative compute tomography</keyword>
	<keyword>Dual X-ray absorptiometry</keyword>
	<keyword>Quality life</keyword>
</DOC>